Drug intelligence / Profile preview

APL-1501 ER + APL-1202

Development stage: Unknown
Lead developer: Asieris Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

APL-1501 ER + APL-1202 is a combination of two related drugs developed by Asieris Pharmaceuticals. APL-1501 ER is an extended-release formulation based on APL-1202 (nitroxoline), designed as a second-generation product with improved druggability through prodrug molecule design. APL-1202 is a reversible and orally available MetAP2 inhibitor with anti-angiogenic and anti-tumor activities, primarily being developed for bladder cancer treatment.

Other names: nitroxoline

Targets

METAP2 (Methionine aminopeptidase 2)

Beyond the preview

Go deeper on APL-1501 ER + APL-1202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL-1501 ER + APL-1202.

Explore the full profile